Cardiovascular Disease

Patients switching from efavirenz to dolutegravir gain more weight at 12 months and have increased risk for hypertension.

Prophylaxis against Pneumocystis jirovecii pneumonia with trimethoprim-sulfamethoxazole reduced the risk for severe infections by nearly 77%, a study found.

Reduced risk for CVD incidence, total mortality, coronary heart disease seen for women with higher adherence

Multifaceted intervention of assessment, education, and feedback increases likelihood of triple prescription fourfold over usual care

Significant gains seen in six-minute walk distance from baseline to week 24

Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.

The table provided is a review of notable updates that occurred in February 2023 for investigational products in development.

Eplontersen is an investigational ligand-conjugated antisense medicine.

Similar favorable functional outcomes seen for both thrombectomy and medical management in patients with distal medium vessel occlusion of anterior cerebral artery

Strategy noninferior for three-year composite of death, myocardial infarction, stroke, or coronary revascularization

The phase 3 trial included 13,970 adults who were unable to maximize or tolerate a statin and had, or were at high risk for, cardiovascular disease.

Risk for in-hospital mortality increased for individuals with heart failure in low dietary sodium group versus usual care

Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Myotoxicity-related fatality rate 3.4 percent after institution of screening coupled with active ventilation, treatment

The FDA is requiring the Company to conduct an additional clinical trial evaluating omecamtiv mecarbil for HFrEF.

The Trifecta and Trifecta GT valves are heart valve replacement devices designed to treat diseased, damaged, or malfunctioning native or prosthetic aortic heart valves.

Emerphed prefilled syringes are ready-to-use and require no assembly.

Nonacceptance of statin therapy associated with longer time to achieve LDL cholesterol of less than 100 mg/dL

Clinical measures of acuity and three-month impairment predicted subsequent therapy doses